CIK 0001730430 · Large accelerated filer
Kiniksa Pharmaceuticals International, plc
Sign in to watch- Ticker
- KNSA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 981795578
- Phone
- 7814319100
- Business address
- 105 PICCADILLY, SECOND FLOOR, LONDON, United Kingdom, W1J 7NJ
- Former names
- Kiniksa Pharmaceuticals, Ltd.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $78,588,440
- in 8 filings, $78.6M under 10b5-1 plans
Net −$78,588,440. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Patel Sanj K −$51.7M CHAIRMAN & CEO sold 42% of stake
- Moat Ross −$9.6M CHIEF OPERATING OFFICER sold 91% of stake
- Paolini John F. −$8.9M CHIEF MEDICAL OFFICER sold 58% of stake
- Megna Michael R −$4.9M CHIEF ACCOUNTING OFFICER sold 80% of stake
- Ragosa Mark −$3.4M CHIEF FINANCIAL OFFICER sold 64% of stake
Reading 59 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-30 | Megna Michael R CHIEF ACCOUNTING OFFICER | Sale 10b5-1 | −3,145 | $96.08 | $302K | 19,738 |
| 2026-10-30 | Megna Michael R CHIEF ACCOUNTING OFFICER | Sale 10b5-1 | −1,691 | $97.11 | $164K | 18,047 |
| 2026-10-30 | Megna Michael R CHIEF ACCOUNTING OFFICER | Sale 10b5-1 | −5,350 | $97.74 | $523K | 12,697 |
| 2026-10-30 | Megna Michael R CHIEF ACCOUNTING OFFICER | Option exercise · Share Option 10b5-1 | −3,932 | 0 | ||
| 2026-10-30 | Megna Michael R CHIEF ACCOUNTING OFFICER | Option exercise · Share Option 10b5-1 | −7,209 | 0 | ||
| 2026-10-30 | Megna Michael R CHIEF ACCOUNTING OFFICER | Option exercise · Share Option 10b5-1 | −4,689 | 2,983 | ||
| 2026-10-30 | Megna Michael R CHIEF ACCOUNTING OFFICER | Option exercise · Share Option 10b5-1 | −4,065 | 16,394 | ||
| 2026-09-03 | Megna Michael R CHIEF ACCOUNTING OFFICER | Sale 10b5-1 | −4,600 | $80.30 | $369K | 29,062 |
| 2026-09-01 | Moat Ross CHIEF OPERATING OFFICER | Option exercise | +2,477 | 14,506 | ||
| 2026-09-01 | Moat Ross CHIEF OPERATING OFFICER | Option exercise | +1,611 | 16,117 | ||
| 2026-09-01 | Moat Ross CHIEF OPERATING OFFICER | Option exercise | +1,740 | 17,857 | ||
| 2026-09-01 | Moat Ross CHIEF OPERATING OFFICER | Option exercise | +2,457 | 20,314 | ||
| 2026-09-01 | Moat Ross CHIEF OPERATING OFFICER | Shares withheld for taxes | −4,007 | $79.28 | $318K | 16,307 |
| 2026-09-01 | Moat Ross CHIEF OPERATING OFFICER | Grant or award · Restricted Share Unit | +9,250 | 9,250 | ||
| 2026-09-01 | Moat Ross CHIEF OPERATING OFFICER | Grant or award · Share Option | +36,950 | 36,950 | ||
| 2026-09-01 | Moat Ross CHIEF OPERATING OFFICER | Option exercise · Restricted Share Unit | −2,457 | 7,371 | ||
| 2026-09-01 | Moat Ross CHIEF OPERATING OFFICER | Option exercise · Restricted Share Unit | −1,740 | 3,481 | ||
| 2026-09-01 | Moat Ross CHIEF OPERATING OFFICER | Option exercise · Restricted Share Unit | −1,611 | 1,611 | ||
| 2026-09-01 | Moat Ross CHIEF OPERATING OFFICER | Option exercise · Restricted Share Unit | −2,477 | 0 | ||
| 2026-09-01 | Ragosa Mark CHIEF FINANCIAL OFFICER | Option exercise | +2,694 | 18,848 |
Page 6 of 74 · 1,467 trades